Marium Khan
Pulmonary Disease · Sheboygan, WINPI 1922539493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 35.8% of the total. Reporting peaked in 2023 at $1,658 and has fallen 81.9% since, to $301 in 2025.
Across 42 payments — averaging $88.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pulmonx Corporation$550
- Sanofi$272
- Johnson & Johnson$251
- GSK$218
- United Therapeutics Corporation$209
- plus $877 from 8 others
What the payments were for
- Food & beverage$3,55196%
- Education$1524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $1,326 |
| Pulmonx Corporation | 8 | $550 |
| Sanofi | 3 | $272 |
| Johnson & Johnson | 2 | $251 |
| GSK | 2 | $218 |
| United Therapeutics Corporation | 2 | $209 |
| Actelion Pharmaceuticals US, Inc. | 2 | $189 |
| Exelixis Inc. | 1 | $162 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $122 |
| Verona Pharma, Inc. | 1 | $121 |
| Insmed, Inc. | 1 | $110 |
| Cook Medical LLC | 2 | $32 |
| Neurelis, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$375
- Monarch Platform$251
- CHARTIS CATHETER$251
- ZEPHYR DELIVERY CATHETER$251
- ZEPHYR ENDOBRONCHIAL VALVE$251
- PULMONX CHARTIS TABLET CONSOLE$251
- DUPIXENT$245
- Cabometyx$162
- SOLIRIS$130
- BREZTRI$126
- NUCALA$125
- Ohtuvayre$121
- Arikayce$110
- UPTRAVI$109
- OPSUMIT$109
How this compares
$3,703 in reported general payments places this provider in the 75th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Sheboygan
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.